BeiGene
BGNE
#881
Rank
A$33.26 B
Marketcap
$302.96
Share price
1.71%
Change (1 day)
0.85%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total assets

Total assets on the balance sheet as of June 2024 : A$8.56 B

According to BeiGene 's latest financial reports the company's total assets are A$8.56 B. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

BeiGene - Total assets on balance sheet (from 2014 to 2024)

Total assets by year

Year Total assets Change
2023-12-31A$8.52 B-9.1%
2022-12-31A$9.37 B-20.14%
2021-12-31A$11.73 B61.51%
2020-12-31A$7.26 B216.9%
2019-12-31A$2.29 B-28.15%
2018-12-31A$3.19 B138.15%
2017-12-31A$1.34 B138.09%
2016-12-31A$0.56 B251.21%
2015-12-31A$0.16 B145.14%
2014-12-31A$65.39 M394.36%
2013-12-31A$13.22 M

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
A$27.25 M-99.68%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.96 B-65.34%๐Ÿ‡บ๐Ÿ‡ธ USA